Bristol-Myers Squibb (BMY) revenue

Revenue · fiscal 2025
$48.20B

Bristol-Myers Squibb (BMY) reported revenue of $48.20B in fiscal 2025 (the year ended December 31, 2025). That is 0.2% lower than the $48.30B of fiscal 2024. Figures as of 18 Nov 2026, 10:54 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$48.20B
Change on fiscal 2024
−0.2%
Growth, 5 years
+2.5% a year
Growth, 10 years
+11.3% a year
Highest on record
$48.30Bfiscal 2024
Lowest on record
$15.62Bfiscal 2007
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Bristol-Myers Squibb revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 2.5% a year; over ten years the rate was 11.3% a year. Across the 19 fiscal years on record (2007–2025), the highest was $48.30B in fiscal 2024 and the lowest $15.62B in fiscal 2007.

History · 19 fiscal years

Revenue by fiscal year

Bristol-Myers Squibb revenue, year by year

Bristol-Myers Squibb (BMY) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$48.20B 0.2% down
2024$48.30B 7.3% up
2023$45.01B 2.5% down
2022$46.16B 0.5% down
2021$46.39B 9.1% up
2020$42.52B 62.6% up
2019$26.15B 15.9% up
2018$22.56B 8.6% up
2017$20.78B 6.9% up
2016$19.43B 17.3% up
2015$16.56B 4.3% up
2014$15.88B 3.1% down
2013$16.39B 7.0% down
2012$17.62B 17.1% down
2011$21.24B 9.0% up
2010$19.48B 3.6% up
2009$18.81B 6.2% up
2008$17.72B 13.4% up
2007$15.62B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Bristol-Myers Squibb and comparable companies
CompanyRevenueFiscal year
Vertex Pharmaceuticals VRTX$12.00B2025
Medtronic MDT$36.36B2026
Bristol-Myers Squibb BMY$48.20B2025
Stryker SYK$25.12B2025
McKesson MCK$403.43B2026
Sanofi SNY€46.72B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BMY

Bristol-Myers Squibb, figure by figure

Bristol-Myers Squibb (BMY) overview: price, valuation and scorecardAll health care companies by market value

Bristol-Myers Squibb revenue: questions and answers

What is Bristol-Myers Squibb's revenue?

Bristol-Myers Squibb (BMY) reported revenue of $48.20B in fiscal 2025 (the year ended December 31, 2025). That is 0.2% lower than the $48.30B of fiscal 2024.

What is the growth rate of Bristol-Myers Squibb's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 2.5% a year; over ten years the rate was 11.3% a year.

What are the highest and lowest revenue figures on record for Bristol-Myers Squibb?

Across the 19 fiscal years on record (2007–2025), the highest was $48.30B in fiscal 2024 and the lowest $15.62B in fiscal 2007.

How is Bristol-Myers Squibb's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Bristol-Myers Squibb it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bristol-Myers Squibb (BMY) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/BMY/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.